Company intelligence / Profile preview
Infirst Healthcare
- Ownership
- Private
- Development stage
- Other
Overview
Infirst Healthcare markets and commercializes well-known OTC brands such as Mylanta and Mylicon (digestive health), Dr. Cocoa (cough and cold), and medical devices, focusing on established molecules and consumer needs in the US retail market. Clinical-stage development is not indicated in public information, as the business is focused on commercialization of established ingredients through brand and formulation innovation.
- Therapeutic areas
- Infectious DiseasesGastroenterology
- Modalities
- Small moleculeDevice
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Infirst Healthcare.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infirst Healthcare.